Page 42 - ஆரோக்கியம் மற்றும் மனிதன் சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ResearchAndMarkets.com s offering. The global drugs for hormonal replacement therapy market is expected to decline from $15.6 billion in 2019 to $13.2 billion in 2020 at a compound annual growth rate (CAGR) of -15.8%. The decline is mainly due to the disruption caused by the lockdown measure across various countries to contain COVID-19 spread. Currently there is less demand for genito-urinary drugs mainly as people are staying at home and are less likely to get exposed to factors that might cause genito-urinary infections, or other hormonal diseases caused by lifestyle changes or eating habits. The market is then expected to recover and grow at a CAGR of 3.5% from 2021 and reach $16.9 billion in 2023.

United statesAsia pacificEli lillyLaura woodNovo nordiskMerck coTeva pharmaceutical industries ltdHealth and human servicesPfizer incBayer agAllergan plcNoven pharmaceuticalsHisamitsu pharmaceutical co incOffice hours callSegmentation by route of administrationE st office hours call